Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Barbara A ParkerRebecca A ShatskyRichard B SchwabAnne M Wallacenull nullDenise M WolfGillian L HirstLamorna Brown-SwigartLaura J EssermanLaura J van 't VeerEmanuela M GhiaChristina YauThomas J KippsPublished in: Breast cancer research and treatment (2023)
High ROR1 or high ROR2 distinctly identified subsets of breast cancer patients with adverse outcomes. Further studies are warranted to determine if high ROR1 or high ROR2 may identify high-risk populations for studies of targeted therapies.